Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
TR Lim Centre for Liver Research and NIHR Biomedical Research Unit in Liver Disease, University of Birmingham and Liver and Hepatobiliary Unit, Queen Elizabeth Hospital Birmingham, UK Abstract: Metabolic syndrome is prevalent in patients with hepatitis C virus (HCV) infection. Given the pandemic s...
Enregistré dans:
Auteur principal: | Lim TR |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2014
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/02779ece64b04fa19406d21e15f85d6b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
par: Kamal SM
Publié: (2014) -
How far are we from the “Treat all” era of antiviral therapy for chronic hepatitis B
par: DING Yang
Publié: (2021) -
Antiviral therapy for chronic hepatitis B in the indeterminate phase is urgent
par: JIANG Jun
Publié: (2021) -
Patients with chronic hepatitis B virus infection in the indeterminate phase may benefit from antiviral therapy
par: XU Jinghang
Publié: (2021) -
Patients in the indeterminate phase of chronic hepatitis B virus infection should receive active antiviral therapy
par: WANG Jingyue
Publié: (2021)